One Step at a Time. Noopur Raje, Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses the results of a practice changing trial, presented at the American Society of Hematolog ASH Conference, confirming the continuous use of lenalidomide in the newly diagnosed myeloma patient.
Metastatic solid tumors are almost invariably fatal. Patients with disseminated small-cell cancers have a particularly unfavorable prognosis, with most succumbing to their disease within two years. Here, we report on the genetic and functional analysis of an outlier curative response of a patient with metastatic small-cell cancer to combined checkpoint kinase 1 CHK1 inhibition and DNA-damaging chemotherapy.
Whole-genome sequencing revealed a clonal hemizygous mutation in the Mre11 complex gene RAD50 that attenuated ATM signaling which in the context of CHK1 inhibition contributed, via synthetic lethality, to extreme sensitivity to irinotecan.
As Mre11 mutations occur in a diversity of human tumors, the results suggest a tumor-specific combination therapy strategy in which checkpoint inhibition in combination with DNA-damaging chemotherapy is synthetically lethal in tumor cells but not normal cells with somatic mutations that impair Mre11 complex function.
Strategies to effect deep and lasting responses to cancer therapy in patients with metastatic disease have remained difficult to attain, especially in early-phase clinical trials.
Here, we present an in-depth genomic and functional genetic analysis identifying RAD50 hypomorphism as a contributing factor to a curative response to systemic combination therapy in a patient with recurrent, metastatic small-cell cancer. Therefore, thoroughly understanding the regulatory mechanisms of miRNAs expression and biogenesis in radiation response will provide new insights for clinical cancer radiotherapy.An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
1 Transmissible Cancer Group, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK. 2 Department of Archaeology, Durham University, Durham, UK. 3 Department of Human Evolution, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany.
4 The Palaeogenomics and Bio. Results from a new study may lead to approval of what could be the first drug that ameliorates potentially deadly reactions in children with severe peanut allergies. The Cancer Genome Anatomy Project CGAP generatesgene expression, polymorphism and chromosomal aberration datasets to support the elucidation of the molecular signatures of cancer.
CGAP generated a wide range of genomics data on cancerous cells that are accessible through easy-to-use online tools. Researchers, educators, and students can find "in silico" answers to biological questions through the CGAP website.
Request a free copy of the CGAP Website Virtual Tour CD from [email protected] to learn how to navigate the website. This session gives you a sneak peek at some of the top-scoring posters across a variety of topics through rapid-fire presentations.
The featured abstracts were chosen by the Program Committee and are marked by a microphone in the online program.